Sleep Support During Menopause: What Research Suggests
Last reviewed: 21 Maret 2026, 7.02
Menopause is one of the most significant and underappreciated disruptors of sleep quality, with research indicating that 40 to 60% of women experience sleep disturbances during the menopausal transition. The causes are multifactorial: declining estrogen and progesterone levels directly affect sleep-regulating neurotransmitter systems, vasomotor symptoms (hot flashes and night sweats) cause frequent awakenings, and the psychological stress of this life transition can contribute to insomnia. Understanding these distinct mechanisms is important because different supplements may address different aspects of menopausal sleep disruption.
Hot flashes and night sweats are the most recognizable menopausal symptoms and are among the most disruptive to sleep. These vasomotor episodes cause a sudden surge in skin temperature, perspiration, and increased heart rate, followed by chills. They can occur multiple times per night, each episode potentially taking 20 to 30 minutes to recover from. Research on supplements for vasomotor symptoms has yielded mixed results, but a few show promise. A 2013 randomized controlled trial found that valerian root (530 mg three times daily) was associated with reduced hot flash severity compared to placebo over 8 weeks. Saffron (30 mg daily) has shown preliminary evidence for reducing hot flash frequency in a 2018 double-blind trial, along with improvements in mood and sexual function. The mechanism may involve serotonergic modulation, as saffron constituents have demonstrated affinity for serotonin receptors, which are involved in thermoregulation.
The hormonal changes of menopause also directly impact sleep architecture. Progesterone, which declines rapidly during perimenopause, has sedative properties and promotes GABA activity. Its loss can contribute to increased sleep onset latency and reduced sleep efficiency. Estrogen influences serotonin metabolism and melatonin production, and its decline may partially explain why postmenopausal women have lower endogenous melatonin levels than premenopausal women. Ashwagandha may be relevant here, as a 2021 study found that 300 mg twice daily for 8 weeks was associated with improvements in menopausal symptoms including sleep disturbance, mood, and hot flashes. Its mechanism in this context likely involves both cortisol modulation and indirect effects on GABA signaling.
Magnesium glycinate is often recommended for menopausal sleep support for multiple reasons: it supports GABA receptor function (partially compensating for the loss of progesterone-mediated GABAergic activity), may help with temperature regulation, and addresses the fact that magnesium intake is often inadequate in postmenopausal women. A 2012 study of elderly subjects, which included a significant proportion of postmenopausal women, found that 500 mg of magnesium daily for 8 weeks was associated with improvements in sleep time, sleep efficiency, and melatonin concentration. Glycine, at 3 grams before bed, may provide additional benefit through its thermoregulatory effects, potentially helping counteract the temperature dysregulation that contributes to night sweats and sleep fragmentation.
It is worth noting that cognitive behavioral therapy for insomnia (CBT-I) has been specifically studied in menopausal women and has demonstrated significant effectiveness. A 2016 JAMA Internal Medicine study found that CBT-I significantly reduced insomnia symptoms in menopausal women, with benefits persisting at 6-month follow-up. Supplements should be viewed as complementary to behavioral interventions and lifestyle modifications such as keeping the bedroom cool (65-67 degrees Fahrenheit), using moisture-wicking bedding, and limiting evening alcohol and spicy foods, which can trigger hot flashes. If menopausal sleep disruption is severe and persistent, discuss the full range of options with your healthcare provider, including hormone replacement therapy, which remains the most effective treatment for vasomotor symptoms when the benefits outweigh the risks for an individual patient.
Hot flashes and night sweats are the most recognizable menopausal symptoms and are among the most disruptive to sleep. These vasomotor episodes cause a sudden surge in skin temperature, perspiration, and increased heart rate, followed by chills. They can occur multiple times per night, each episode potentially taking 20 to 30 minutes to recover from. Research on supplements for vasomotor symptoms has yielded mixed results, but a few show promise. A 2013 randomized controlled trial found that valerian root (530 mg three times daily) was associated with reduced hot flash severity compared to placebo over 8 weeks. Saffron (30 mg daily) has shown preliminary evidence for reducing hot flash frequency in a 2018 double-blind trial, along with improvements in mood and sexual function. The mechanism may involve serotonergic modulation, as saffron constituents have demonstrated affinity for serotonin receptors, which are involved in thermoregulation.
The hormonal changes of menopause also directly impact sleep architecture. Progesterone, which declines rapidly during perimenopause, has sedative properties and promotes GABA activity. Its loss can contribute to increased sleep onset latency and reduced sleep efficiency. Estrogen influences serotonin metabolism and melatonin production, and its decline may partially explain why postmenopausal women have lower endogenous melatonin levels than premenopausal women. Ashwagandha may be relevant here, as a 2021 study found that 300 mg twice daily for 8 weeks was associated with improvements in menopausal symptoms including sleep disturbance, mood, and hot flashes. Its mechanism in this context likely involves both cortisol modulation and indirect effects on GABA signaling.
Magnesium glycinate is often recommended for menopausal sleep support for multiple reasons: it supports GABA receptor function (partially compensating for the loss of progesterone-mediated GABAergic activity), may help with temperature regulation, and addresses the fact that magnesium intake is often inadequate in postmenopausal women. A 2012 study of elderly subjects, which included a significant proportion of postmenopausal women, found that 500 mg of magnesium daily for 8 weeks was associated with improvements in sleep time, sleep efficiency, and melatonin concentration. Glycine, at 3 grams before bed, may provide additional benefit through its thermoregulatory effects, potentially helping counteract the temperature dysregulation that contributes to night sweats and sleep fragmentation.
It is worth noting that cognitive behavioral therapy for insomnia (CBT-I) has been specifically studied in menopausal women and has demonstrated significant effectiveness. A 2016 JAMA Internal Medicine study found that CBT-I significantly reduced insomnia symptoms in menopausal women, with benefits persisting at 6-month follow-up. Supplements should be viewed as complementary to behavioral interventions and lifestyle modifications such as keeping the bedroom cool (65-67 degrees Fahrenheit), using moisture-wicking bedding, and limiting evening alcohol and spicy foods, which can trigger hot flashes. If menopausal sleep disruption is severe and persistent, discuss the full range of options with your healthcare provider, including hormone replacement therapy, which remains the most effective treatment for vasomotor symptoms when the benefits outweigh the risks for an individual patient.